Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL11030447 | 0.83 | TAAR1 (0.61) | TAAR1GAAKDM4ESMN1; SMN2HTT | |
| SCHEMBL28596017 | 0.79 | TAAR1 (0.63) | TAAR1GAAKDM4ESMN1; SMN2HTT | |
| Hydrochloric Acid SCHEMBL14719130 | 0.78 | TAAR1 (0.61) | TAAR1GAAKDM4ESMN1; SMN2HTT | |
| SCHEMBL7701701 | 0.75 | TAAR1 (0.52) | TAAR1GAAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5205493 | 0.75 | TAAR1 (0.46) | TAAR1GAAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL13615074 | 0.73 | TAAR1 (0.44) | TAAR1GAAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL129391 | 0.71 | TAAR1 (0.43) | TAAR1GAAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL113326 | 0.71 | TAAR1 (0.48) | TAAR1GAAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL7030193 | 0.71 | TAAR1 (0.43) | TAAR1GAAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL91337 | 0.71 | KDM4E (0.45) | TAAR1GAAKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | claimed |
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | disclosed |
| CN-108368107-B | Fused heterocyclic compounds as S1P modulators | 艾伯维公司 | 2021-11-26 | — | — | CN | disclosed |
| US-10556907-B2 | Fused heterocyclic compounds as S1P modulators | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-02-11 | — | — | US | disclosed |
| CN-108368107-A | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | 艾伯维公司 | 2018-08-03 | — | — | CN | disclosed |
| EP-3341369-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017036978-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | ABBVIE INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20170057966-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-02 | — | — | US | disclosed |
| US-8859546-B2 | Picolinamide inhibitors of kinases | ABBVIE INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2665711-A1 | PICOLINAMIDE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| US-20090131472-A1 | P38 Kinase Inhibiting Agents | MERCK SHARP & DOHME LLC | 2009-05-21 | — | — | US | disclosed |
| US-20090088436-A1 | P38 Kinase Inhibiting Agents | MERCK SHARP & DOHME CORP. | 2009-04-02 | — | — | US | disclosed |
| US-7482345-B2 | P38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. | 2009-01-27 | — | — | US | disclosed |
| EP-1963314-A2 | P38 KINASE INHIBITING AGENTS | Merck & Co., Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| EP-1915373-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS P38 KINASE INHIBITING AGENTS | Merck and Co., Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| US-20080009478-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| WO-2007067478-A2 | P38 KINASE INHIBITING AGENTS | MERCK & CO., INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070129372-A1 | P38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. | 2007-06-07 | — | — | US | disclosed |
| WO-2007021710-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS P38 KINASE INHIBITING AGENTS | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2005042491-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131472-A1 | P38 Kinase Inhibiting Agents | MAPK1, MAPK8, MAPK7 | ACHE 1613/4885TAAR1 1800/4885GAA 1582/4885 |
| US-20170057966-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | S1PR1, S1PR2, S1PR3 | ACHE 4688/4885TAAR1 630/4885GAA 4173/4885 |
| US-20080009478-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | HTR2C, HTR2A, HTR2B | ACHE 1360/4885TAAR1 110/4885GAA 1606/4885 |
| US-20090088436-A1 | P38 Kinase Inhibiting Agents | MAPK1, MAPK8, MAPK7 | ACHE 1473/4885TAAR1 1654/4885GAA 1757/4885 |
| US-20070129372-A1 | P38 kinase inhibiting agents | MAPK1, MAPK8, MAPK7 | ACHE 1473/4885TAAR1 1654/4885GAA 1757/4885 |
| US-10556907-B2 | Fused heterocyclic compounds as S1P modulators | S1PR1, S1PR2, S1PR3 | ACHE 4688/4885TAAR1 630/4885GAA 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.